HNE

Edison issues flash on Henderson EuroTrust (HNE): Proposed merger with Henderson European Focus Trust

Retrieved on: 
Wednesday, April 10, 2024
Janus, HNE, HEFT, Philosophy, Security (finance)

On 14 March, the boards of Henderson European Focus Trust (HEFT) and Henderson EuroTrust (HNE) announced the proposed merger of the two companies to form Henderson European Trust.

Key Points: 
  • On 14 March, the boards of Henderson European Focus Trust (HEFT) and Henderson EuroTrust (HNE) announced the proposed merger of the two companies to form Henderson European Trust.
  • The resulting enlarged fund will be managed by Janus Henderson Investors’ (JHI’s) European equities team.
  • There will be two co-managers, Tom O’Hara (currently co-lead manager of HEFT) and Jamie Ross (currently lead manager of HNE).
  • There will be two dividend payments a year; payments are expected to normalise at the end of FY25 (30 September).

ENTRÉE RESOURCES ANNOUNCES FISCAL YEAR 2023 RESULTS and REVIEWS CORPORATE HIGHLIGHTS

Retrieved on: 
Friday, March 8, 2024
Hearing, Technical report, Conversation, Tribunal, Mining, Technical, ETG, Attention, Sandstorm Gold, Minority, Mineral, Copper, Rio Tinto, Oyu Tolgoi mine, Management, Toronto Stock Exchange, Rail transport, HNE, State, Panel, Partnership, Total, Aerodrome, Multilateral, National Instrument 43-101, Exchange, TSX, Capital, Government, National instrument, Shaft, Movement

VANCOUVER, BC, March 8, 2024 /PRNewswire/ - Entrée Resources Ltd. (TSX: ETG) (OTCQB: ERLFF) – the "Company" or "Entrée") has today filed its annual operational and financial results for the year ended December 31, 2023.

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ - Entrée Resources Ltd. (TSX: ETG) (OTCQB: ERLFF) – the "Company" or "Entrée") has today filed its annual operational and financial results for the year ended December 31, 2023.
  • As at December 31, 2023, 86 Lift 1 Panel 0 draw bells had been opened, including 67 draw bells during 2023.
  • Construction of Primary Crusher 2 commenced in December 2023 and is expected to be completed by the end of 2025.
  • Technical studies for Panels 1 and 2 mine design and schedule optimization were completed by OTLLC during the second quarter 2023.

EQS-News: Henderson EuroTrust (HNE): Initiation – Searching for mispriced quality

Retrieved on: 
Thursday, February 2, 2023
Janus, Janus Henderson, JHI, HNE, AIC, Research, Security (finance)

Henderson EuroTrust (HNE) provides relatively concentrated exposure to a portfolio of continental European (ex-UK) equities.

Key Points: 
  • Henderson EuroTrust (HNE) provides relatively concentrated exposure to a portfolio of continental European (ex-UK) equities.
  • Ross is part of a well-established, collegiate European equities desk at Janus Henderson Investors (JHI) that covers the breadth of available opportunities in the region.
  • HNE has historically traded at a high single to low double-digit discount, which we believe is unjustified.
  • Click here to view the full report or here to sign up to receive research as it is published.

MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

Retrieved on: 
Thursday, July 7, 2022
Review, FDA, Patient, Decision-making, Biopsy, European Medicines Agency, Protein, Research, Chemokine, Form 20-F, Trial of the century, Burn, GLOBE, Biomarker, Infection, COVID-19, Element, Growth, Union, U.S. Securities and Exchange Commission, Reactive oxygen species, Phrase, Lipid, Polysaccharide, Cytokine, Annual report, Inflammation, Regeneration, Bromelain (pharmacology), Ulcer, Organic acid, Development, Debridement, Bacteria, Food, Contract, Wound healing, EPS, BARDA, SEC, VLU, Incidence, DFU, Mouth ulcer, Government, Matrix metalloproteinase, Food and Drug Administration Amendments Act of 2007, Safety, Leg, Security (finance), Sewage, Pharmaceutical industry, Hospital, Medical imaging, Medical device, HNE

YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced positive results from its U.S. prospective, open-label, single-arm, Phase 2 pharmacology clinical study of EscharEx® for the debridement of lower leg ulcers.

Key Points: 
  • The study was designed to evaluate the clinical performance, safety and pharmacology effect of EscharEx in debridement of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).
  • The U.S. phase 2 pharmacology study was a prospective, open label, single-arm study, being conducted at three U.S. clinical sites.
  • The study evaluated the clinical performance, safety, and pharmacology effect of EscharEx in the debridement of lower leg ulcers (VLUs and DFUs).
  • The study evaluated the safety and efficacy of debridement as measured by incidence of, and time to complete debridement.

Entrée Resources Files Amended Technical Report for its Interest in the Entrée/Oyu Tolgoi Joint Venture Property

Retrieved on: 
Thursday, October 21, 2021
PEA, Budget, Canadian Securities Administrators, Nature, Disclosure, COVID-19, Health, Accident, IFRS, NPV, Tax, Metal, Heads of Agreement (1981), Sandstorm Gold, Transport, Insurance, Private Securities Litigation Reform Act, Panel, Silver, Risk, Company, News, Video news release, Water, Statistics, Mineral, Industry, Resource management, SEDAR, Amend, Conversation, Phrase, Environment, Gold, Metallurgy, Hugo, Legislation, AG, ASIC, Mining, HNE, Mineral resource classification, National instrument, Copper, Reserved cases, Person, Review, MT, Treaty of friendship and alliance between the Government of Mongolia and Tibet, National Instrument 43-101, Economics, Rio Tinto, Coronavirus, Lithium, Animal, Cryptocurrency, Risk management

Mineral Reserves in the 2021 Reserve Case, and Mineral Resources in the 2021 PEA mine plan are reported on a 100% basis.

Key Points: 
  • Mineral Reserves in the 2021 Reserve Case, and Mineral Resources in the 2021 PEA mine plan are reported on a 100% basis.
  • Attributable Entre/Oyu Tolgoi JV production begins in 2031 and ramps up to stable production in 2043.
  • Entre Resources Ltd. is a well-funded Canadian mining company with a unique carried joint venture interest on a significant portion of one of the world's largest copper-gold projects the Oyu Tolgoi project in Mongolia.
  • Entre has a 20% or 30% carried participating interest in the Entre/Oyu Tolgoi JV, depending on the depth of mineralization.

ConvaTec Selects Veeva Vault CDMS for Biomarker Study in Wound Infections

Retrieved on: 
Thursday, September 23, 2021
Veeva Systems, EDC, PH, HNE, Data management, Biomarker, Professional corporation, Infection, CDMS, ConvaTec, MPO, NYSE, Industry, Enzyme, Medical device, Medical imaging

PLEASANTON, Calif., Sept. 23, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic conditions, has selected Veeva Vault CDMS to provide electronic data capture ( EDC ), coding , and data cleaning for their upcoming study on the detection of wound infections.

Key Points: 
  • PLEASANTON, Calif., Sept. 23, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic conditions, has selected Veeva Vault CDMS to provide electronic data capture ( EDC ), coding , and data cleaning for their upcoming study on the detection of wound infections.
  • This proof-of-concept study will explore the effectiveness of a novel combination of biomarkers, pH, HNE, and MPO, in detecting wound infection.
  • Veeva MedTech is proud to support companies like ConvaTec with Vault CDMS, a unified data management solution for clinical data capture, cleaning, and coding.
  • Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
    Veeva is the global leader in cloud software for the life sciences industry.

ConvaTec Selects Veeva Vault CDMS for Biomarker Study in Wound Infections

Retrieved on: 
Thursday, September 23, 2021
Veeva Systems, EDC, PH, HNE, Data management, Biomarker, Twitter, Professional corporation, Infection, CDMS, ConvaTec, MPO, NYSE, Industry, Enzyme, Medical device, Medical imaging

BARCELONA, Spain, Sept. 23, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic conditions, has selected Veeva Vault CDMS to provide electronic data capture (EDC), coding, and data cleaning for their upcoming study on the detection of wound infections.

Key Points: 
  • BARCELONA, Spain, Sept. 23, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic conditions, has selected Veeva Vault CDMS to provide electronic data capture ( EDC ), coding , and data cleaning for their upcoming study on the detection of wound infections.
  • This proof-of-concept study will explore the effectiveness of a novel combination of biomarkers, pH, HNE, and MPO, in detecting wound infection.
  • Veeva MedTech is proud to support companies like ConvaTec with Vault CDMS, a unified data management solution for clinical data capture, cleaning, and coding.
  • Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veeva_eu on Twitter: twitter.com/veeva_eu
    Veeva is the global leader in cloud software for the life sciences industry.

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Retrieved on: 
Monday, March 1, 2021
Peptidase, Medical specialties, Elastase, Branches of biology, HNE, Cystic fibrosis, Neutrophil elastase, Cystic Fibrosis Foundation

Pratteln, Switzerland, March1, 2021 Santhera Pharmaceuticals (SIX:SANN) announces positive results from its multiple ascending dose Phase 1b study with lonodelestat, a potent inhibitor of human neutrophil elastase (hNE), in patients with cystic fibrosis (CF).

Key Points: 
  • Pratteln, Switzerland, March1, 2021 Santhera Pharmaceuticals (SIX:SANN) announces positive results from its multiple ascending dose Phase 1b study with lonodelestat, a potent inhibitor of human neutrophil elastase (hNE), in patients with cystic fibrosis (CF).
  • Lonodelestat is a potent and selective peptide inhibitor of human neutrophil elastase (hNE), currently being developed in cystic fibrosis (CF).
  • Santhera acknowledges the support of the Cystic Fibrosis Foundation (CFF) by providing funding for the conduct of the Phase 1a and 1b safety trials with lonodelestat.
  • Results showed a linear dose-exposure relationship over the dose range from 40mg to 160mg, with no accumulation in plasma or sputum.

Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis

Retrieved on: 
Tuesday, September 10, 2019
Medical specialties, Branches of biology, Cystic Fibrosis Foundation, Elastase, HNE, Anthera Pharmaceuticals, Neutrophil elastase, Organ systems, Cystic fibrosis, Vertex Pharmaceuticals, Cystic Fibrosis Canada

Pratteln, Switzerland, September10, 2019 Santhera Pharmaceuticals (SIX: SANN) announces the online publication of Phase I data with its human neutrophil elastase (hNE) inhibitor POL6014 in the Journal of Cystic Fibrosis [1].

Key Points: 
  • Pratteln, Switzerland, September10, 2019 Santhera Pharmaceuticals (SIX: SANN) announces the online publication of Phase I data with its human neutrophil elastase (hNE) inhibitor POL6014 in the Journal of Cystic Fibrosis [1].
  • POL6014 is an innovative, potent and selective inhibitor of human neutrophil elastase (hNE) in clinical development for the treatment of cystic fibrosis (CF).
  • We are encouraged by these early data in healthy volunteers and patients with cystic fibrosis.
  • The Cystic Fibrosis Foundation (CFF) is providing funding support for the conduct of the safety trials with POL6014.